PATENT CLAIM ANALYSIS

Application Number: 16221006
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "277000"]

Abstract:
The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

Claim (Index 7):
The compound according to  claim 1 , wherein R 5  is hydrogen.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 98.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15842823', '14580045', '13651312', '15232892', '11698781']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7404185294141913
- 35 USC 102 Novelty (BERT): 0.6908691548558248
- Combined Prediction Score: 0.7354635919583546
- Mean Citation Score: 419.942236
- Max Citation Score: 793.0178
- Similarity Product: 659.7499367872596

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test